Market
Story
Russia to Launch Free Personalized mRNA Cancer Vaccine Targeting Neoantigens in 2025
Dec 28, 2024, 08:02 AM
Russian scientists have developed a personalized mRNA vaccine aimed at treating cancer, with plans to launch it in early 2025. The vaccine, which will be free for Russian citizens, is designed to train the immune system to recognize and target cancer cells by identifying mutations called neoantigens. The development involves the National Medical Research Centre of the Russian Ministry of Health and the Gamaleya National Research Center of Epidemiology, the latter known for its work on the Sputnik V vaccine. The vaccine is expected to cost the state 300,000 rubles per dose, targeting cancers such as melanoma, lung, gastrointestinal, and possibly kidney cancers. This breakthrough comes amidst ongoing geopolitical tensions, highlighting Russia's focus on advancing medical research.
View original story
Similar markets
Breast Cancer • 25%
Other • 25%
Colon Cancer • 25%
Lung Cancer • 25%
Other types • 25%
Breast cancer • 25%
Prostate cancer • 25%
Lung cancer • 25%
Breast Cancer • 25%
Other • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
None • 25%
Europe • 25%
Asia • 25%
Both Europe and Asia • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Prostate Cancer • 25%
Other • 25%
Other • 25%
China • 25%
Brazil • 25%
India • 25%
Successful with minor issues • 25%
Trials delayed • 25%
Successful with no major issues • 25%
Unsuccessful • 25%
Yes • 50%
No • 50%
No Major Approval • 25%
WHO Approval • 25%
EU Approval • 25%
US FDA Approval • 25%